Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

23.31 +0.41 (+1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
From Pacira BioSciences
Via GlobeNewswire
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 12 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 16 companies set new 52-week lows. 
Via Benzinga
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences's Return On Capital Employed Insights
Via Benzinga
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 49 companies hit new 52-week lows. 
Via Benzinga
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
Via Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021 
From Pacira BioSciences
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug
Via Benzinga
Pacira BioSciences' Return On Capital Employed Overview
  
Via Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences: Q3 Earnings Insights
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira BioSciences Reports Third Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September -- 
From Pacira BioSciences
Via GlobeNewswire
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Pacira BioSciences: Q2 Earnings Insights
  Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday. 
Via Benzinga
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75. 
Via Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
Via Investor's Business Daily
Vertex Pharmaceuticals Receives Composite Rating Upgrade
The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals. 
Via Investor's Business Daily
Pacira BioSciences's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback